Tech Company Inital Public Offerings
scPharmaceuticals IPO
Headquartered in Burlington, scPharmaceuticals completed its IPO.
Transaction Overview
Company Name
Announced On
11/16/2017
Transaction Type
IPO
Amount
$89,600,000
Proceeds Purpose
We currently intend to use the net proceeds from this offering, together with our existing unrestricted cash, as follows: approximately $35 million to $42 million for the pre-commercial planning and commercialization of Furoscix, if approved, including the development of our sales and marketing infrastructure; approximately $6 million to $8 million for the automation necessary to increase manufacturing capacity for our sc2Wear Infusor; approximately $10 million to $25 million for research and development, including for our infectious diseases program; and the remaining for working capital and other general corporate purposes. Based on our current plans, we believe our existing unrestricted cash, together with the net proceeds from this offering, will be sufficient to fund our operations for at least 24 months following this offering.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
2400 District Ave. 310
Burlington, MA 01803
USA
Burlington, MA 01803
USA
Phone
Website
Email Address
Overview
scPharmaceticals (NASDAQ: SCPH) is creating innovative and important new therapeutic options by administering drugs subcutaneously using a convenient two component delivery system suitable for patient self-administration.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Tucker
Chief Financial Officer
Troy Ignelzi
Chief Operating Officer
Abraham Ceesay
Browse more venture capital transactions:
Prev: 11/16/2017: Outpost Medicine venture capital transaction
Next: 11/16/2017: eASIC venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC transactions reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs